The Adjuvant Activity of Alphavirus Replicons Is Enhanced by Incorporating the Microbial Molecule Flagellin into the Replicon

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Knudsen, Maria L ^a   Johansson, Daniel X ^a   Kostic, Linda ^b   Nordström, Eva K L ^a   Tegerstedt, Karin ^a   Pasetto, Anna ^a   Applequist, Steven E ^c   Ljungberg, Karl ^a   Sirard, Jean Claude ^d,e,f,g   Liljeström, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d INSERM U1019   (France)

^e INSERM   (France)

^f CNRS   (France)

^g UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLAGELLIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2C; IMMUNOLOGICAL ADJUVANT; INTERFERON; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ALPHA VIRUS; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FLIC GENE; INNATE IMMUNITY; MOUSE; NONHUMAN; REPLICON; SALMONELLA TYPHIMURIUM; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CRICETINAE; FLAGELLIN; GENE EXPRESSION; IMMUNOGLOBULIN G; INTERFERON TYPE I; MICE; MICE, KNOCKOUT; REPLICON; SALMONELLA TYPHIMURIUM; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 5;

ALPHAVIRUS; BACTERIA (MICROORGANISMS); MUS; SALMONELLA TYPHIMURIUM;

EID: 84878973350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065964     Document Type: Article

References (64)

1. Coffman RL, Sher A, Seder RA, (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
2. Pasare C, Medzhitov R, (2005) Control of B-cell responses by Toll-like receptors. Nature 438: 364-368.
3. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125.
4. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, et al. (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203: 413-424.
5. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, et al. (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
6. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A, (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6: 769-776.
7. Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J, (2007) Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol 247: 72-84.
8. Mäkelä SM, Österlund P, Julkunen I, (2011) TLR ligands induce synergistic interferon-beta and interferon-lambda1 gene expression in human monocyte-derived dendritic cells. Mol Immunol 48: 505-515.
9. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, et al. (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 178: 1164-1171.
10. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, et al. (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410: 1099-1103.
11. Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Ozoren N, et al. (2006) Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 7: 576-582.
12. Miao EA, Alpuche-Aranda CM, Dors M, Clark AE, Bader MW, et al. (2006) Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 7: 569-575.
13. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD, (2003) The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 170: 5165-5175.
14. Arimilli S, Johnson JB, Clark KM, Graff AH, Alexander-Miller MA, et al. (2008) Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function. J Virol 82: 10975-10985.
15. Tosch C, Geist M, Ledoux C, Ziller-Remi C, Paul S, et al. (2009) Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy. Cancer Gene Ther 16: 310-319.
16. Ahmed M, Puckett S, Arimilli S, Braxton CL, Mizel SB, et al. (2010) Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin. J Virol 84: 12093-12098.
17. Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, et al. (2007) Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25: 763-775.
18. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214.
19. McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, et al. (2007) A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 195: 1607-1617.
20. Applequist SE, Rollman E, Wareing MD, Liden M, Rozell B, et al. (2005) Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 175: 3882-3891.
21. Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, et al. (2008) Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 82: 11813-11823.
22. Didierlaurent A, Ferrero I, Otten LA, Dubois B, Reinhardt M, et al. (2004) Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol 172: 6922-6930.
23. Nempont C, Cayet D, Rumbo M, Bompard C, Villeret V, et al. (2008) Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol 181: 2036-2043.
24. McSorley SJ, Ehst BD, Yu Y, Gewirtz AT, (2002) Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 169: 3914-3919.
25. Cuadros C, Lopez-Hernandez FJ, Dominguez AL, McClelland M, Lustgarten J, (2004) Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 72: 2810-2816.
26. Mizel SB, Bates JT, (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185: 5677-5682.
27. Bates JT, Uematsu S, Akira S, Mizel SB, (2009) Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol 182: 7539-7547.
28. Vijay-Kumar M, Carvalho FA, Aitken JD, Fifadara NH, Gewirtz AT, (2010) TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur J Immunol 40: 3528-3534.
29. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, et al. (2011) Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29: 5145-5152.
30. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, et al. (2010) Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28: 8268-8274.
31. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, et al. (2011) Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29: 4897-4902.
32. Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, et al. (2010) Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 5: e14442.
33. Vassilieva EV, Wang BZ, Vzorov AN, Wang L, Wang YC, et al. (2011) Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant. MBio 2: e00328-00310.
34. Cunningham AF, Khan M, Ball J, Toellner KM, Serre K, et al. (2004) Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol 34: 2986-2995.
35. Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, et al. (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
36. Pichlmair A, Reis e Sousa C, (2007) Innate recognition of viruses. Immunity 27: 370-383.
37. Schulz O, Pichlmair A, Rehwinkel J, Rogers NC, Scheuner D, et al. (2010) Protein kinase R contributes to immunity against specific viruses by regulating interferon mRNA integrity. Cell Host Microbe 7: 354-361.
38. Ventoso I, Sanz MA, Molina S, Berlanga JJ, Carrasco L, et al. (2006) Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev 20: 87-100.
39. Barry G, Breakwell L, Fragkoudis R, Attarzadeh-Yazdi G, Rodriguez-Andres J, et al. (2009) PKR acts early in infection to suppress Semliki Forest virus production and strongly enhances the type I interferon response. J Gen Virol 90: 1382-1391.
40. Hidmark ÅS, McInerney GM, Nordström EK, Douagi I, Werner KM, et al. (2005) Early alpha/beta interferon production by myeloid dendritic cells in response to UV-inactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88. J Virol 79: 10376-10385.
41. Glasgow GM, McGee MM, Sheahan BJ, Atkins GJ, (1997) Death mechanisms in cultured cells infected by Semliki Forest virus. J Gen Virol 78 (Pt 7): 1559-1563.
42. Barry G, Fragkoudis R, Ferguson MC, Lulla A, Merits A, et al. (2010) Semliki forest virus-induced endoplasmic reticulum stress accelerates apoptotic death of mammalian cells. J Virol 84: 7369-7377.
43. Hidmark ÅS, Nordström EK, Dosenovic P, Forsell MN, Liljeström P, et al. (2006) Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J Virol 80: 7100-7110.
44. Thompson JM, Whitmore AC, Konopka JL, Collier ML, Richmond EM, et al. (2006) Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A 103: 3722-3727.
45. Smerdou C, Liljeström P, (1999) Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol 73: 1092-1098.
46. Karlsson GB, Liljestrom P, (2003) Live viral vectors: Semliki Forest virus. Methods Mol Med 87: 69-82.
47. Sjöberg EM, Suomalainen M, Garoff H, (1994) A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology (N Y) 12: 1127-1131.
48. Ryan MD, Drew J, (1994) Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J 13: 928-933.
49. Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, et al. (2001) Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol 82: 1013-1025.
50. Rumbo M, Sierro F, Debard N, Kraehenbuhl JP, Finke D, (2004) Lymphotoxin β receptor signaling induces the chemokine CCL20 in intestinal epithelium. Gastroenterology 127: 213-223.
51. Uematsu S, Jang MH, Chevrier N, Guo Z, Kumagai Y, et al. (2006) Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 7: 868-874.
52. Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, et al. (2003) Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 4: 1247-1253.
53. Thompson JM, Whitmore AC, Staats HF, Johnston R, (2008) The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 26: 4998-5003.
54. Zhou X, Berglund P, Zhao H, Liljeström P, Jondal M, (1995) Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci U S A 92: 3009-3013.
55. Sanders CJ, Franchi L, Yarovinsky F, Uematsu S, Akira S, et al. (2009) Induction of adaptive immunity by flagellin does not require robust activation of innate immunity. Eur J Immunol 39: 359-371.
56. Sundbäck M, Douagi I, Dayaraj C, Forsell MN, Nordström EK, et al. (2005) Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles. Virology 341: 190-202.
57. Näslund TI, Uyttenhove C, Nordström EK, Colau D, Warnier G, et al. (2007) Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J Immunol 178: 6761-6769.
58. Liu F, Yang J, Zhang Y, Zhou D, Chen Y, et al. (2010) Recombinant flagellins with partial deletions of the hypervariable domain lose antigenicity but not mucosal adjuvancy. Biochem Biophys Res Commun 392: 582-587.
59. Ben-Yedidia T, Arnon R, (1998) Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol Lett 64: 9-15.
60. Honko AN, Sriranganathan N, Lees CJ, Mizel SB, (2006) Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 74: 1113-1120.
61. Ha H, Lee JH, Kim HN, Kwak HB, Kim HM, et al. (2008) Stimulation by TLR5 modulates osteoclast differentiation through STAT1/IFN-beta. J Immunol 180: 1382-1389.
62. Huber JP, Farrar JD, (2011) Regulation of effector and memory T-cell functions by type I interferon. Immunology 132: 466-474.
63. Fink SL, Cookson BT, (2007) Pyroptosis and host cell death responses during Salmonella infection. Cell Microbiol 9: 2562-2570.
64. Vijay-Kumar M, Sanders CJ, Taylor RT, Kumar A, Aitken JD, et al. (2007) Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 117: 3909-3921.